Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) EBIAT: 2009-2025

Historic EBIAT for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $2.0 million.

  • Aytu Biopharma's EBIAT rose 33.31% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year decrease of 153.02%. This contributed to the annual value of -$14.2 million for FY2025, which is 10.49% up from last year.
  • As of Q3 2025, Aytu Biopharma's EBIAT stood at $2.0 million, which was up 109.61% from -$20.4 million recorded in Q2 2025.
  • Aytu Biopharma's 5-year EBIAT high stood at $4.0 million for Q1 2025, and its period low was -$53.3 million during Q1 2022.
  • Its 3-year average for EBIAT is -$3.4 million, with a median of -$2.5 million in 2023.
  • As far as peak fluctuations go, Aytu Biopharma's EBIAT crashed by 1,058.35% in 2023, and later skyrocketed by 238.34% in 2025.
  • Aytu Biopharma's EBIAT (Quarterly) stood at -$11.5 million in 2021, then surged by 42.04% to -$6.7 million in 2022, then spiked by 109.25% to $619,000 in 2023, then climbed by 27.30% to $788,000 in 2024, then skyrocketed by 33.31% to $2.0 million in 2025.
  • Its EBIAT stands at $2.0 million for Q3 2025, versus -$20.4 million for Q2 2025 and $4.0 million for Q1 2025.